Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2000
03/16/2000WO2000013668A1 Microparticles
03/16/2000WO2000013667A1 Lipstatin derivative-soluble fiber tablets
03/16/2000WO2000013664A1 Drug preparations for treating sexual dysfunction
03/16/2000WO2000013662A2 Medicated chewing gum delivery system for nicotine
03/16/2000WO2000013654A2 A carotenoid composition containing phytoene and phytofluene
03/16/2000WO2000013653A1 Organosilicone compositions for personal care
03/16/2000WO2000013648A2 Method for the preparation of citalopram
03/16/2000WO2000013647A1 Method and device for producing tablets
03/16/2000WO2000013529A1 Foods for preventing vomiting
03/16/2000WO2000013509A1 Method of determining and reducing the risk of bph-related urologic events
03/16/2000WO2000008014A8 Disubstituted bicyclic heterocycles having, in particular, a thrombin inhibitive effect
03/16/2000WO2000005206A8 Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
03/16/2000WO2000002897A3 Delta cleavage products and methods based thereon
03/16/2000WO2000002881A3 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein
03/16/2000WO2000000500A3 Polyketides and their synthesis
03/16/2000WO2000000212A8 Promoting nitric oxide and cyclic gmp activity
03/16/2000WO2000000188A3 Synthetically prepared hydroxy citric acid composition for the treatment and/or prophylaxis of overweight and use thereof
03/16/2000WO1999067252A3 Epothilone derivatives and their synthesis and use
03/16/2000WO1999066912A3 Method of treating pulmonary hypertension
03/16/2000WO1999065910A9 Fused azepinone cyclin dependent kinase inhibitors
03/16/2000WO1999064047A9 Novel antiviral compounds
03/16/2000WO1999063979A3 Inhibition of δ-9-desaturase activity by saponins
03/16/2000WO1999063929A9 Multibinding inhibitors of microsomal triglyceride transferase protein
03/16/2000WO1999060131A3 Hemorrhagic enteritis virus dna sequences, proteins encoded thereby and various uses thereof
03/16/2000WO1999059499A3 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
03/16/2000WO1999055706A9 Imidazo pyridine derivatives which inhibit gastric acid secretion
03/16/2000WO1999050403A9 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
03/16/2000WO1999048501A9 Voacamine as anti-malarial agent and anti-malarial agent containing voacamine
03/16/2000WO1999043636A3 Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
03/16/2000WO1999030548B1 Method for the preparation of citalopram
03/16/2000DE19849017C1 Dressing for promoting wound healing contains a viscous oily extract of cinnamon leaves
03/16/2000DE19841930A1 Stabile, pulverförmige Lycopin-Formulierungen, enthaltend Lycopin mit einem Kristallinitätsgrad von größer 20% Sturdy, powder-like lycopene formulations comprising lycopene having a degree of crystallinity of greater than 20%
03/16/2000DE19841534A1 Treating autonomic nervous system dysfunction, especially vagal dysfunction of the heart, uses new or known benzenesulfonyl (thio)urea derivatives optionally in combination with beta-blockers
03/16/2000DE19841244A1 Verfahren und Vorrichtung zum Herstellen von Tabletten Method and apparatus for the manufacture of tablets
03/16/2000DE19841209A1 Slow-release caffeine tablets produced by direct compression of caffeine-containing plant materials or extracts
03/16/2000DE19841051A1 Treating male or female sexual dysfunction, especially erectile dysfunction, using propentofylline or corresponding alcohol as selective phosphodiesterase V inhibitor
03/16/2000CA2343637A1 Organosilicone compositions for personal care
03/16/2000CA2343536A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000CA2343531A1 Gaba uptake inhibitors having a pyrrolidine structure
03/16/2000CA2343522A1 Methods for treating or preventing viral infections and associated diseases
03/16/2000CA2343234A1 Method and device for producing tablets
03/16/2000CA2343168A1 Piperidine derivatives
03/16/2000CA2343027A1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
03/16/2000CA2342994A1 Kappa agonist compounds and pharmaceutical formulations thereof
03/16/2000CA2342943A1 Novel nitrophenylaziridine compounds and their use as prodrugs
03/16/2000CA2342898A1 Unsaturated hydroximic acid derivatives as parp inhibitors
03/16/2000CA2342882A1 Chemokine receptor antagonists and methods of use therefor
03/16/2000CA2342862A1 Nocathiacin antibiotic derivatives prepared by microbial biotransformation
03/16/2000CA2342858A1 Method of screening compounds useful in the treatment of a desease caused by or exacerbated by mpv
03/16/2000CA2342855A1 Novel pyranoses
03/16/2000CA2342800A1 Nanogel networks and biological agent composition thereof
03/16/2000CA2342796A1 Preventives/remedies for multiple organ failure
03/16/2000CA2342769A1 Drug preparations for treating sexual dysfunction
03/16/2000CA2342625A1 Lipstatin derivative-soluble fiber tablets
03/16/2000CA2342349A1 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
03/16/2000CA2342284A1 Methylation of plasmid vectors
03/16/2000CA2342280A1 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
03/16/2000CA2341782A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
03/16/2000CA2341777A1 Neutral amino acid transporter and gene thereof
03/16/2000CA2341752A1 Methods and compositions for the prevention or treatment of cancer
03/16/2000CA2341353A1 Substituted dihydrobenzopyrans useful as antiarrhythmic agents
03/16/2000CA2341338A1 G-motif oligonucleotides and uses thereof
03/16/2000CA2341325A1 Method of stimulating prosaposin receptor activity
03/16/2000CA2308472A1 Ophthalmic compositions and process of using
03/16/2000CA2306165A1 Composition for improving mental capabilities in mammals
03/15/2000EP0986164A1 Brush holder
03/15/2000EP0985679A1 New hydroxy derivatives of tylosin and process for their preparation
03/15/2000EP0985671A1 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT
03/15/2000EP0985666A1 Substituted indole compounds as COX-2 inhibitors
03/15/2000EP0985415A1 Uracil reductase inactivators
03/15/2000EP0985414A2 Method of treating glaucoma and ischemic retinopathy
03/15/2000EP0985411A1 Sterol esters in tableted solid dosage forms
03/15/2000EP0985403A2 Gelatinous composition
03/15/2000EP0985038A1 Sodium channel receptor
03/15/2000EP0985035A2 Dna methyltransferase genomic sequences and antisense oligonucleotides
03/15/2000EP0984983A2 Modulators of intracellular inflammation, cell death and cell survival pathways containing a card and a kinase domain
03/15/2000EP0984982A1 Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them
03/15/2000EP0984980A1 20-ARALKYL-5$g(a)-PREGNANE DERIVATIVES
03/15/2000EP0984975A1 Multicyclic erythromycin derivatives
03/15/2000EP0984971A1 Vanadium complexes and derivatives thereof and methods related thereto
03/15/2000EP0984970A1 Spiro-quinuclidine derivatives, their preparation and use
03/15/2000EP0984969A1 Fused dihydropyrans
03/15/2000EP0984968A1 Salts of aromatic sulphonic acids
03/15/2000EP0984967A1 Naphthyridine derivatives and their analogues inhibiting cytomegalovirus
03/15/2000EP0984966A1 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS
03/15/2000EP0984965A1 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
03/15/2000EP0984963A1 Novel compounds
03/15/2000EP0984961A1 Novel pyridine derivatives and pharmaceutical compositions containing them
03/15/2000EP0984960A1 N-triazolyl-2-indolecarboxamides and their use as cck-a agonists
03/15/2000EP0984959A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
03/15/2000EP0984957A1 NOVEL FORM OF $i(S)OMEPRAZOLE
03/15/2000EP0984956A1 Indoline derivatives as 5ht2c receptor antagonists
03/15/2000EP0984955A1 SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNF$g(a) LEVELS
03/15/2000EP0984954A1 Anti-mitotic agents which inhibit tubulin polymerization
03/15/2000EP0984952A1 A new salt
03/15/2000EP0984947A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality
03/15/2000EP0984943A1 Azacyclooctane and heptane derivatives, their preparation and usein therapy
03/15/2000EP0984940A1 Cyanoamidines as cell proliferation inhibitors
03/15/2000EP0984939A1 Cyanoguanidines as cell proliferation inhibitors
03/15/2000EP0984938A1 Cyanoguanidines as cell proliferation inhibitors
1 ... 6348 6349 6350 6351 6352 6353 6354 6355 6356 6357 6358 6359 6360 6361 6362 6363 6364 6365 6366 6367 6368 ... 7860